secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempus AI, Inc. (TEM)
CIK:        0001717115
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-064419
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempus Q1 revenue up 75.4% to $255.7M; raises FY2025 revenue guidance to $1.25B
-------------------------------------------------------------------------------

- Revenue $255.7M (+75.4% YoY); gross profit $155.2M (+99.8% YoY) with margin improvement in Genomics and Data & Services.
- Net loss $68.0M (incl. $28.2M stock comp & $31.8M fair value losses); adjusted EBITDA -$16.2M vs -$43.9M YoY.
- Collaborations with AstraZeneca and Pathos; $200M in data licensing/model development fees over 3 years.
- Full year 2025 revenue guidance raised to ~$1.25B (~80% growth); expects positive adjusted EBITDA of $5M.
- Genomics revenue $193.8M (+88.9% YoY); Data & Services revenue $61.9M (+43.2% YoY; Insights up 58%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1717115/000095017025064419/0000950170-25-064419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1717115/000095017025064419/tem-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-064419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer